The Lynx Group

Lung Cancer

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial, which evaluated sotorasib (Lumakras), a small-molecule inhibitor of the KRAS p.G12C mutation, in previously treated patients with non–small-cell lung cancer (NSCLC) whose tumors express this aberration. These results were simultaneously published in the New England Journal of Medicine.
Read Article

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. These findings were presented by Patrick Forde, MBBCh, Associate Professor of Oncology and Director of the Thoracic Cancer Clinical Research Program at Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, during the virtual 2021 American Association for Cancer Research Annual Meeting.
Read Article

On September 15, 2021, the FDA accelerated the approval of mobocertinib (Exkivity; Takeda Pharmaceuticals), a tyrosine kinase inhibitor, for the treatment of adults with locally advanced or metastatic non−small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by the FDA-approved Oncomine Dx Target Test (Life Technologies Corporation), which was approved on the same day as a companion diagnostic for mobocertinib. The FDA granted mobocertinib priority review, breakthrough therapy designation, and orphan drug designation.
Read Article

Treatment with the immune checkpoint inhibitor atezolizumab (Tecentriq) following surgical resection and chemotherapy significantly improved disease-free survival (DFS) compared with best supportive care (BSC) alone in patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and tumor composite score PD-L1 ≥1%, according to interim results from the phase 3 IMpower010 clinical trial, which were presented at the ASCO 2021 virtual annual meeting.
Read Article

On May 28, 2021, the FDA accelerated the approval of sotorasib (Lumakras; Amgen), an oral KRAS inhibitor of the RAS GTPase family, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) associated with KRAS G12C mutation, as determined by an FDA-approved test, after ≥1 systemic therapies. The FDA granted sotorasib orphan drug and breakthrough therapy designations.
Read Article

On May 21, 2021, the FDA accelerated the approval of amivantamab-vmjw (Rybrevant; Janssen/Johnson & Johnson), a bispecific antibody targeting mutations in the EGFR and MET pathways, for adults with non–small-cell lung cancer (NSCLC) that is associated with EGFR exon 20 insertion mutations, as detected by the FDA-approved Guardant360 CDx test, which was approved on the same day as a companion diagnostic for amivantamab. The FDA had granted amivantamab a breakthrough therapy designation for this indication.
Read Article

The COVID-19 pandemic has had a profound impact on healthcare, especially in the management of patients with cancer, who are often not seeking healthcare in the same way as before the pandemic. At the 2021 International Association for the Study of Lung Cancer (IASLC) meeting, experts discussed the implications for patients with lung cancer, specifically.
Read Article

Approximately 13% of patients with lung adenocarcinomas harbor KRAS p.G12C mutations. In the phase 2 CodeBreaK 100 clinical trial, the responses to sotorasib in patients with advanced non–small-cell lung cancer (NSCLC) and KRAS p.G12C mutation were early, deep, and durable, according to Bob T. Li, MD, PhD, MPH, Medical Oncologist, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. He presented the study results at the 2021 International Association for the Study of Lung Cancer meeting.
Read Article

Sexual orientation and assigned sex at birth are significant determinants in the utilization of lung cancer screening, according to an analysis from the Behavioral Risk Factor Surveillance System (BRFSS) 2018, a cross-sectional, nationally representative database, that looked at screening among lesbian, gay, bisexual, transgender (LGBT) populations.
Read Article

Genomic analysis of lung cancer in women who have never smoked may reveal novel mutations and structural alterations. Such an analysis, said Sitapriya Moorthi, PhD, Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, may suggest unique opportunities for future target identification and therapeutic intervention. Dr Moorthi discussed the results of a mutational analysis of the Women’s Health Initiative Cohort that were presented at the 2021 International Association for the Study of Lung Cancer meeting.
Read Article

Page 1 of 8

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: